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Abstract
Objective: Weight variation during therapy has been described as a useful marker to predict TB treatment outcome. No
previous study has used longitudinal analysis to corroborate this finding. The goal of this study was to evaluate change and
trends of patients’ bodyweight over time depending on TB treatment outcome.
Methods and Findings: A retrospective cohort study with all TB cases diagnosed from 2000 to 2006 was carried out.
Information from 5 public tuberculosis treatment facilities at Pampas de San Juan de Miraflores, Lima, Peru was analyzed.
Poor outcome was defined as failure or death during TB therapy, and compared to good outcome defined as cured.
Longitudinal analysis with a pre-specified marginal model was fitted using Generalized Estimating Equations to compare
weight trends for patients with good and poor outcome adjusting for potential confounders. A total of 460 patients (55.4%
males, mean age: 31.6 years) were included in the analysis: 42 (9.1%) had a poor outcome (17 failed and 25 died). Weight at
baseline was not different comparing outcome groups (p=0.17). After adjusting for age, gender, type of TB, scheme of
treatment, HIV status and sputum variation during follow-up, after the first month of treatment, patients with good
outcome gained, on average, almost 1 kg compared to their baseline weight (p,0.001), whereas those with poor outcome
lost 1 kg (p=0.003). Similarly, after 4 months, a patient with good outcome increased 3 kg on average (p,0.001), while
those with poor outcome only gained 0.2 kg (p=0.02).
Conclusions: Weight variation during tuberculosis therapy follow-up can predict treatment outcome. Patients losing weight
during TB treatment, especially in the first month, should be more closely followed as they are at risk of failure or death.
Citation: Bernabe-Ortiz A, Carcamo CP, Sanchez JF, Rios J (2011) Weight Variation over Time and Its Association with Tuberculosis Treatment Outcome: A
Longitudinal Analysis. PLoS ONE 6(4): e18474. doi:10.1371/journal.pone.0018474
Editor: Adithya Cattamanchi, San Francisco General Hospital, University of California San Francisco, United States of America
Received January 6, 2011; Accepted March 1, 2011; Published April 8, 2011
Copyright:  2011 Bernabe-Ortiz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: antonio.bernabe@upch.pe
Introduction
During 2009, 9.4 million new tuberculosis (TB) cases were
estimated with about 3% occurring in the Americas [1]. An
estimated 440,000 cases were caused by multi-drug-resistant TB
(MDR-TB) and Peru is one of the countries reporting cases of
extensively drug-resistant TB (XDR-TB) [1].
In most countries, TB patients usually receive MDR-TB testing
if they fail to treatment after surviving at least 5 months of empiric
therapy with a standardized first-line antibiotic regimen [2,3].
Peru has the highest rate of MDR-TB in the Americas, with 5.3%
MDRTB in new TB cases, 24% in re-treatment cases and more
than 200 cases of XDR-TB reported by 2008 [1,4].
TB is a wasting disease [5,6,7,8] and bodyweight variation has
been proposed as a practical anthropometric marker to predict TB
treatment outcome [9,10,11,12]. Moreover, weight loss of 2 kg. or
more during the first-month therapy has been considered as
a potential risk factor for toxicity due to drugs [13]. Many
countries, including Peru, routinely weigh patients and repeat
sputum microscopy tests on a monthly basis during therapy to
assess treatment response. Several studies have reported that
positive sputum microscopy at second month of treatment is
associated with subsequent treatment failure, but is insensitive at
population level [2,14,15,16]. Thus, patients’ bodyweight might be
a helpful and cheap test to predict TB treatment outcome.
Although many papers have reported bodyweight as a marker to
predict therapy failure, death or relapse, to our knowledge, no
study has reported an appropriate longitudinal analysis of patients
during TB treatment assessing bodyweight change over time.
Longitudinal data analysis is a statistical technique that allows the
direct study of within-individual change over time accounting for
within-individual correlation in the analysis [17].
The objective of this paper was to assess change of patients’
bodyweight over time depending on TB treatment outcome. This
model was adjusted for several potential confounders. We
hypothesized that the trends of patients’ bodyweight with poor
outcome, those who had died or failed during treatment, differed
from those who had ended treatment as cured.
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Study design, setting and participants
Data from a retrospective cohort of patients commencing
tuberculosis therapy was used and analyzed for this study. This
research used programmatic TB diagnosis,treatment monitoring and
outcome data as recorded from the National Health Strategy for
Prevention and Control of Tuberculosis (ESN-PCT) at 5 public
tuberculosis treatment facilities in Pampas de San Juan de Miraflores,
a periurban shantytown located at the south of Lima, Peru.
Patients included in the analysis were at least 18 years old and
diagnosed with tuberculosis disease between 2000 and 2006. We
deliberately choose these years because changes on TB treatment
monitoring occurred starting 2007 in the ESN-PCT. We excluded
patients if they were restarting partially completed or interrupted
TB treatment or therapy had failed within the previous 12 months
because this group has a high level of drug resistance and
therefore, evolution of these patients is completely different [2,3].
Outcomes and variables of interest
The main outcome of the study was bodyweight, recorded in
kilograms (kg) from treatment start (baseline) and repeatedly
measured in a monthly basis. For this study, only data from the
first 5 months were used for analysis.
The ESN-PCT defines treatment failure based on positive
sputum microscopy results after $5 months of treatment or
reverting to positive after two consecutive negative monthly results
[18]. Deaths were defined as those patients who died during
tuberculosis therapy follow-up. For our research, we dichotomized
these programmatic outcomes in ‘cured’ (good outcome), or to
have had an adverse or poor outcome (death or treatment failure,
as previously defined).
Other variables of interest included in the analysis were: age
measured in years, patient sex (male or female), type of tuberculosis
(pulmonary vs. extra-pulmonary), treatment scheme (new vs.
recurrent), change of sputum during treatment assessed monthly,
and HIV status (positive vs. unknown). Since HIV test is not
habitually performed among TB cases and no patients was found to
be HIV negative, we categorized this variableas positive or unknown.
Procedures
All patients were treated by the TB programme with empiric
standardizedfirst-linetherapyandclinic-based direct-observationof
every dose (DOTS approach) [19]. The Peruvian TB programme
uses monthly food packages as adherence incentives and these are
standardized and given for all patients. Management of TB cases
included programmatic monitoring with monthly sputum micros-
copy and weight (kg) measures [18]. For microscopy, the TB
programme used un-concentrated direct Ziehl-Neelsen smear
microscopy with a well-established national quality assurance
system. For weighing, data from records taking from the existing
clinic scales and established programmatic training for their use was
utilized. The accuracy of the scales used was not systematically
confirmed but each patient was weighed repeatedly using the same
scale and weights were generally recorded to the nearest 0.1 kg.
Data analysis
Data were analyzed using STATA version 11.0 for Windows
(STATA Corporation, College Station, Texas, US). First, a brief
description of demographic and clinical characteristics was
tabulated. Second, weight was calculated for each group according
to our outcome of interest and month of follow-up. Finally, a
longitudinal analysis was carried out to evaluate weight change
over time. A marginal model was fitted using Generalized
Estimating Equations to model average weight trends for patients
with good and poor outcome [20]. The crude model was specified
as follow:
Yij~b0zb1:Outcomezb2:Tijzb3:Tij:Outcome
Where Yij is the mean weight (kg) in patient ‘‘i’’ at time ‘‘j’’, b0 is
the intercept, i.e. weight in kilograms among those with good
outcome at baseline, b1 is the difference in weight in patients with
poor outcome compared to those with good outcome at baseline,
b2 quantifies the change in weight between baseline and one
selected month for participants with good outcome, and the sum of
b2 and b3 (interaction term) represents the change in weight
between baseline and one selected month for participants with a
poor outcome [17]. In this model, the time variable was included
as categorical because weight over time did not show linearity in
the poor outcome group.
Quasi-likelihood under the independence model information
criterion (QIC) [20], an extension of the Akaike’s information
criterion (AIC), was applied to find the best working correlation
structure applicable for the proposed model. Additionally, the
model was adjusted for potential confounders affecting both
outcome and weight. Potential confounders included were age,
sex, type of tuberculosis, treatment scheme, HIV status, and sputum
microscopy result change during treatment. Wald test was used to
report p-values, whereas robust standard errors were used to
calculate 95% confidence intervals for each coefficient in the model.
Ethics issues
Institutional review board (IRB) approval for this project was
granted by Universidad Peruana Cayetano Heredia. Informed
consent was waived by IRB because of use of routine and
programmatic data of the National Health Strategy for Control
and Prevention of Tuberculosis.
Results
Description at baseline
A total of 530 patients started tuberculosis treatment during the
period of study and were eligible for this study; but, 20 moved away
before starting treatment, 37 abandoned therapy, 11 had previous
failures, and 2 had unknown outcomes. Therefore, 460 (87%)
patients were included in the analysis, 55.4% of them were males
and the mean age was 31.6 years (SD: 14.1; range: 18–80). Of the
total, 42 (9.1%) had a poor outcome at the end of tuberculosis
therapy (17 failed and 25 died). A brief description of patients’
characteristics in relation to outcome status is shown in Table 1.
Weight during treatment follow-up
Table 2 shows a detailed description of weight variation during
treatment follow-up without accounting for intra-subject correla-
tion. There was no significant difference between weights of
outcome groups at baseline (p=0.12); however, on average,
weight decreased in those who developed an adverse outcome
whereas it increased among those who ended treatment as cured.
Weight change over time
When assessing correlation structure for repeated measurements
using QIC, the best working correlation was exchangeable. Other
structures (auto-regressive, unstructured, and non-stationary) were
evaluated with the model, but they did not achieve convergence.
In any case, robust standard errors were used to handle
misspecification of variance or correlation functions [20].
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18474Results of crude and adjusted marginal models are shown in
Table 3. Of interest, adjusted coefficient for adverse outcome was
not significant (p=0.17), indicating that the difference in weight
(about 2 kg) among patients with poor and good outcome at
baseline was not statistically different. However, the interaction
terms together were significant (Wald test for interaction,
p=0.002) indicating that changes of weight over time among
patients with poor outcome differed of those with good outcome
(Figure 1). Based on the results of the adjusted model (Table 3), at
the end of the first month, on average, patients with good outcome
gained almost 1 kg (0.93 kg according to the adjusted model)
compared to their baseline, whereas at the fourth month, weight
increased about 3 kg. On the other hand, patients with poor
outcome lost about 1 kg (0.97 kg according to the model) at the
first month of therapy compared to the baseline, while gaining
0.2 kg after four months of treatment. Moreover, patients with
poor outcome did not gain weight during the first two months of
therapy.
Discussion
This study shows that, after adjusting for potential confounders,
the curve of weight over time among patients who developed
adverse outcome is completely different from patients classified as
cured at the end of follow-up. The association continues being
statistically significant after having included the monthly sputum
microscopy result as confounder [14,15,21,22], pointing out that
change in weight over time is an independent predictor of
treatment outcome.
These findings might have an important impact on public
health, especially in resource-constrained settings. Weight assess-
ment might be an easy, cheap, and useful form to predict TB
treatment outcome among patients receiving therapy. Weight after
the end of the first month of therapy, characterized by bodyweight
loss among those with poor outcome, might be very important to
avoid deaths or failures. Remarkably, most of the divergence of
weight over time occurred during the first month. After that,
weight gain among poor outcome patients shows parallel trends
compared to good outcome ones with, however, a lower rate.
Prospective studies with standardized measurements are needed to
corroborate these findings.
Tuberculosis is the archetypal wasting disease. The association
of TB and nutrition status has long been evident, as older terms
were used for tuberculosis such as the Greek term ‘‘phthisis’’ or ‘‘to
waste away’’ [23]. Some current guidelines mention that weight
loss may indicate incipient treatment failure and have been
recently included in our National Health Strategy for Control and
Prevention of Tuberculosis [18]. Recently, some studies have
started to report that weight loss should be considered as clinically
relevant [9,10,11,12,24]. One previous study reported that
moderate and severe malnutrition was a risk factor associated
with early death during TB treatment in rural areas of Malawi
[25]. However, to our knowledge, no study has used longitudinal
data analysis to show changes and trends of patients’ bodyweight
during treatment follow-up.
Previous studies have suggested an association between meager
weight gain during tuberculosis therapy and risk of poor treatment
outcome [11,12] or relapse [10]. One of these studies reported that
patients under DOTS gained 3.2 kg on average at the end of
treatment. We found similar results in our good outcome group
(3.3 kg at the end of five months of therapy) [12]. The other two
studies identified a cutoff of 5% weight gain to predict tuberculosis
treatment outcome [10,11]. Khan et al used the 5% cutoff at the
end of the intensive therapy phase (first two months) [10], whereas
Krapp et al reported the usefulness of the same cutoff but at the
end of the therapy [11]. Our findings suggest that we can apply
strategies as soon as the end of the first month to avoid deaths and
failures, including MDR testing, supplemental nutrition and closer
monitoring. A total of 16 of 17 patients who failed treatment in
this study were diagnosed as MDR-TB cases after failing (data not
shown). On the other hand, other two different studies have shown
that appropriate therapy is associated with progressive nutritional
recovery and restoration of nutrition-related markers [7,26], but
Table 1. Characteristics of enrolled patients at baseline
according to outcome status*.
Variable
Good outcome
(n=418)
Poor outcome
(n=42) p-value
Sex
Female 187 (44.7%) 18 (42.9%) 0.82
Male 231 (55.3%) 24 (57.1%)
Age (years)
Mean (SD) 30.8 (13.2) 39.4 (19.5) ,0.001
Type of tuberculosis
Extra-pulmonary 67 (16.1%) 7 (16.7%) 0.92
Pulmonary 350 (83.9%) 35 (83.3%)
Scheme of treatment
New 360 (86.1%) 28 (66.7%) 0.001
Recurrent 58 (13.9%) 14 (33.3%)
Sputum result
Negative 118 (29.0%) 9 (23.1%) 0.64
1+ 155 (38.1%) 15 (38.5%)
2+ 73 (17.9%) 10 (25.6%)
3+ 61 (15.0%) 5 (12.8%)
HIV infection**
Unknown 414 (9.0%) 39 (92.9%) 0.002
Yes 4 (1.0%) 3 (7.1%)
Days of follow-up
Mean (SD) 196 (38.6) 134 (74.9) ,0.001
*Results may not add due to missing values.
**Only 7 patients were known to be HIV-positive because HIV testing is rarely
performed.
doi:10.1371/journal.pone.0018474.t001
Table 2. Weight change over time during follow-up
according to outcome status.
Weight (kg) Treatment outcome
Good outcome Poor outcome
N Mean (SD) N Mean (SD)
Baseline 418 54.7 (8.3) 42 52.5 (9.2)
First month 412 56.0 (8.4) 39 50.6 (9.7)
Second month 405 56.8 (8.5) 33 49.5 (10.3)
Third month 401 57.7 (8.3) 29 51.7 (10.2)
Fourth month 389 58.3 (8.4) 26 53.7 (8.7)
Fifth month 389 58.7 (8.7) 18 51.0 (13.1)
doi:10.1371/journal.pone.0018474.t002
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total arm muscle circumference, fat mass, serum albumin, bone
minerals and protein mass, despite marked weight gain in patients.
Strengths of this study include the use of programmatic data to
assess bodyweight change among TB patients commencing
treatment; the use of longitudinal analysis with the best working
correlation structure taking into account several potential
confounders including changes on sputum microscopy results
during follow-up, one of the well-known predictors of TB
treatment outcome; and the assessment of weight trends during
5 consecutive months after beginning therapy. Many studies have
reported findings using bodyweight variation during the first two
Figure 1. Weight change over time during treatment follow-up according to outcome status (adjusted model*). * Predicted lines were
adjusted for age, gender, type of tuberculosis, scheme of treatment, HIV status, and sputum variation during follow-up.
doi:10.1371/journal.pone.0018474.g001
Table 3. Crude and adjusted marginal models assessing weight change over time according to outcome status.
Crude model Adjusted model*
b 95%CI p-value b 95%CI p-value
Intercept 54.70 53.90; 55.50 ,0.001 56.91 53.09; 60.73 ,0.001
Poor outcome 22.25 25.13; 0.64 0.127 22.07 25.04; 0.90 0.172
Time (1st month) 1.46 1.24; 1.68 ,0.001 0.93 0.54; 1.31 ,0.001
Time (2nd month) 2.24 1.96; 2.52 ,0.001 1.67 1.24; 2.10 ,0.001
Time (3rd month) 3.01 2.68; 3.33 ,0.001 2.42 1.95; 2.89 ,0.001
Time (4th month) 3.58 3.23; 3.92 ,0.001 2.97 2.49; 3.46 ,0.001
Time (5th month) 3.93 3.56; 4.30 ,0.001 3.33 2.82; 3.84 ,0.001
Poor outcome* Time (1st month) 22.35 23.54; 21.15 ,0.001 21.90 23.16; 20.64 0.003
Poor outcome* Time (2nd month) 23.18 24.98; 21.39 0.001 22.56 24.32; 20.80 0.004
Poor outcome* Time (3rd month) 22.90 25.16; 20.64 0.012 22.05 23.64; 20.46 0.011
Poor outcome* Time (4th month) 23.41 25.58; 21.25 0.002 22.81 25.15; 20.48 0.018
Poor outcome* Time (5th month) 23.07 25.75; 20.39 0.025 21.25 23.76; 1.27 0.331
*Adjusted by age, gender, type of tuberculosis, scheme of treatment, HIV status, and sputum variation during follow-up.
doi:10.1371/journal.pone.0018474.t003
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analyzed trends of bodyweight over time.
However, this study has also several limitations. First, we joined
potential treatment outcomes which might lead to misclassification.
Although, we collected 6-years information, we only found a small
number of failures and deaths occurred during the period of the
study. However, our findings agreed with previous reports showing
the association between weight and TB treatment outcome. Further
studies with greater sample sizes are needed to corroborate our
findings. Second, socioeconomic information, a very important
variable to predict patients’ weight, was not available from data.
Nevertheless, our cohort was located in a poor, periurban
shantytown community where members of TB-affected families
have been determined to live on less that USS | 1 dollar per day.
Third, during the period of the study, HIV infection status was not
routinely determined among TB patients. As a result, misclassifi-
cation can have occurred because cases detected were diagnosed
due to suspect for the presence of symptoms or opportunistic
infections. HIV prevalence found in this study (1.5%) was similar to
previous reports in Peru though [29,30]. Finally, deaths due to TB
occurred during the first months of therapy (64% of deaths took
place before completing four month of therapy, which might have
reduced the power to detect difference of weights at the fifth month
of follow-up (Table 3). However, the use of generalized estimating
equations can protect against missing data if this is believed to be at
random. In addition, the idea of the paper was to evaluate how
trends of bodyweight change would have occurred in real life using
programmatic data for this purpose.
In summary, our findings reveal that trends and change of
weight during tuberculosis therapy can predict treatment outcome.
Thus, weight loss during the first month of therapy should be used
as part of routinely clinical evaluation to take appropriate
decisions. These patients should be more closely followed as they
are at risk of adverse outcomes. Follow-up monitoring might
include MDR diagnosis testing, supplemental nutrition, closer
monitoring, HIV infection status, treatment of opportunistic
infections, etc. Further studies are needed to find appropriate
weight loss cutoff including sensitivity and specificity analysis, and
assess the combination of sputum microscopy results with weight
change over time to predict TB treatment outcomes.
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